
#### NYSTATIN- nystatin cream cream Preferred Pharmaceuticals, Inc.

-----

#### DESCRIPTION

Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei.

Structural formula:



## C<sub>47</sub>H<sub>75</sub>NO<sub>17</sub> Molecular Weight: 926.13

Nystatin Cream, USP is for dermatologic use.

Nystatin cream for topical use, contains 100,000 USP nystatin units per gram in a cream base containing aluminum hydroxide gel, ceteareth-15, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, purified water, simethicone emulsion, sorbitol solution, titanium dioxide, white petrolatum, methylparaben, propylparaben, and sodium hydroxide.

## CLINICAL PHARMACOLOGY

#### Pharmacokinetics

Nystatin is not absorbed from intact skin or mucous membrane.

#### Microbiology

Nystatin is an antibiotic which is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi, including *Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.* Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides)* become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no

appreciable activity against bacteria, protozoa, or viruses.

### **INDICATIONS AND USAGE**

Nystatin Cream, USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

## This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.

## CONTRAINDICATIONS

Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

## PRECAUTIONS

#### General

# Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

#### **INFORMATION FOR THE PATIENT**

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.

2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

## Laboratory Tests

If there is a lack of therapeutic response, KOH smears, cultures or other diagnostic methods should be repeated.

#### Carcinogenesis, Mutagenesis, and Impairment of Fertility

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin

or the effects on male or female fertility.

#### Pregnancy

Teratogenic Effects

Category C

Animal reproduction studies have not been conducted with any nystatin cream. It also is not known whether this cream can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin cream should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

## **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

## Pediatric Use

Safety and effectiveness have been established in the pediatric population from birth to 16 years.

(See DOSAGE AND ADMINISTRATION.)

#### Geriatric Use

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.

#### (See **PRECAUTIONS: General.**)

To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

#### **DOSAGE AND ADMINISTRATION**

## Adults and Pediatric Patients (Neonates and Older)

Apply liberally to affected areas twice daily or as indicated until healing is complete.

#### HOW SUPPLIED

Nystatin Cream, USP is a smooth yellow cream.

Nystatin Cream, USP is supplied in 15g (NDC **68788-8234-1**) and 30 g (NDC **68788-8234-3**) tubes providing 100,000 USP Nystatin units per gram.

**Store at 20° to 25°C (68° to 77°F)** [see USP Controlled Room Temperature]. Avoid freezing.

#### **Distributed by:**

Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080

Rev. 03/2022 8-0678CPLNC2 VC7625

#### Relabeled By: Preferred Pharmaceuticals, Inc.

#### PRINCIPAL DISPLAY PANEL

NDC 68788-8234


Nystatin Cream, USP

**Rx only** 

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Cosette Pharmaceuticals, Inc.

Relabeled By: Preferred Pharmaceuticals, Inc.



# NYSTATIN

nystatin cream cream

nystatin cream cream										
Ρ	roduct Inform	mation								
Ρ	roduct Type		HUMAN PRESCRIPTION DRUG		em Code Source)	NDC: 0678	C:68788-8234(NDC:0713- 78)			
R	oute of Adminis	stration	TOPICAL							
Active Ingredient/Active Moiety										
Ingredient Name					Basis of Stre	ength	Strength			
Nystatin (UNII: BDF101C72E) (Nystatin					Nystatin	-	100000 [USP'U] in 1 g			
Inactive Ingredients										
			Ingredient Name				Strength			
AI	geldrate (UNII: 03	BJ11K103C)								
Ce	eteareth-15 (UNII	: 867H4YOZ8Z	)							
	yceryl Monostea									
	opylene Glycol (		7V3)							
	ater (UNII: 059QF									
	methicone (UNII:									
	orbitol (UNII: 506T									
	tanium Dioxide (		(4)							
	etrolatum (UNII: 4		\ \							
	<b>ethylparaben</b> (UN <b>opylparaben</b> (UN									
	odium Hydroxide									
	-									
Polyethylene Glycol 400 (UNII: B697894SGQ)										
Ρ	roduct Chara	cteristics								
Color		YELLOW	Score							
Sł	hape			Size	Size					
Flavor				Impr	Imprint Code					
С	ontains									
-										
P	ackaging									
#	ltem Code	Pac	kage Description		Marketing Date	Start	Marketing End Date			
1	NDC:68788- 8234-1	1 in 1 CARTON	1 CARTON		08/09/2022					
1		15 g in 1 TUBE; Type 0: Not a Combination Product								
2	NDC:68788- 8234-3	1 in 1 CARTON	I		08/09/2022					
2	30 g in 1 TUBE; Type 0: Not a Combination Product									

Marketing Information									
Application Number or Monograph Citation	Marketing Start Date	Marketing End Date							
ANDA061966	08/09/2022								
	Application Number or Monograph Citation	Application Number or MonographMarketing StartCitationDate							

Labeler - Preferred Pharmaceuticals, Inc. (791119022)

**Registrant -** Preferred Pharmaceuticals, Inc. (791119022)

Establishment									
Name	Address	ID/FEI	<b>Business Operations</b>						
Preferred Pharmaceuticals, Inc.		791119022	RELABEL(68788-8234)						

Revised: 7/2024

Preferred Pharmaceuticals, Inc.